Vaginal estrogen therapy for patients with breast cancer

Geburtshilfe und Frauenheilkunde

Volumn 73, Issue 10, 2013, Pages 1017-1022

  Moegele, M ^a   Buchholz, S ^a   Seitz, S ^a   Lattrich, C ^a   Ortmann, O ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

breast cancer; hormone therapy; quality of life; vaginal atrophy

Indexed keywords

ANDROGEN RECEPTOR; AROMATASE INHIBITOR; BENZOYL PEROXIDE; DIETHYLSTILBESTROL; ESTRADIOL; ESTRIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; GESTAGEN; GYNOFLOR; HORMONE RECEPTOR; JENAPHARM; LINOLADIOL HN; OEKOLP FORTE; OEKOLP FORTE KOMBI; OEKOLP OVULA FORTE; OESTRO GYNAEDRON; PLACEBO; PROGESTERONE; TESTOSTERONE; TIBOLONE; UNCLASSIFIED DRUG; XAPRO;

BLADDER; BREAST CANCER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CYSTITIS; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DYSPAREUNIA; ENDOMETRIUM HYPERPLASIA; FOLLOW UP; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; META ANALYSIS; PETECHIA; QUALITY OF LIFE; RECURRENT INFECTION; REVIEW; RISK ASSESSMENT; SYMPTOM; SYSTEMATIC REVIEW; TABLET; URETHRA; VAGINA ATROPHY; VAGINA EPITHELIUM; VAGINA RING; VAGINAL DRYNESS; VAGINAL LUBRICATION; VAGINITIS; VENOUS THROMBOEMBOLISM;

EID: 84887490880     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0033-1350876     Document Type: Review

References (47)

1. Levi F., Bosetti C., Lucchini F. et al. Monitoring the decrease in breast cancer mortality in Europe. Eur J Cancer Prev: 2005; 14 497 502 (Pubitemid 41689648)
2. Couzi R. J., Helzlsouer K. J., Fetting J. H. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol: 1995; 13 2737 2744
3. Ganz P. A., Rowland J. H., Desmond K. et al. Life after breast cancer: understanding womenÊs health-related quality of life and sexual functioning. J Clin Oncol: 1998; 16 501 514 (Pubitemid 28135592)
4. Baumgart J., Nilsson K., Stavreus-Evers A. et al. Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer. Am J Obstet Gynecol: 2011; 204 26.e1 26.e7
5. Chin S. N., Trinkaus M., Simmons C. et al. Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer. Clin Breast Cancer: 2009; 9 108 117
6. Jones S. E., Cantrell J., Vukelja S. et al. Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy. J Clin Oncol: 2007; 25 4765 4771 (Pubitemid 350086479)
7. Eisemann N., Waldmann A., Katalinic A. Epidemiology of breast cancer - current figures and trends. Geburtsh Frauenheilk: 2013; 73 130 135
8. Cella D., Fallowfield L. J. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat: 2008; 107 167 180 (Pubitemid 350265697)
9. North American Menopause Society The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of the North American Menopause Society. Menopause: 2007; 14 355 369
10. Ortmann O., Dören M., Windler E. Hormone therapy in perimenopause and postmenopause (HT): interdisciplinary S3 guideline, Association of the Scientific Medical Societies in Germany AWMF 015/062-short version. Arch Gynecol Obstet: 2011; 284 343 355
11. Fick E-M, Anzeneder T., Katalinic A. et al. Bisphosphonates and their role in therapy for breast cancer - results from the PATH Biobank. Geburtsh Frauenheilk: 2013; 73 412 421
12. Rossouw J. E., Anderson G. L., Prentice R. L. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the WomenÊs Health Initiative randomized controlled trial. JAMA: 2002; 288 321 333 (Pubitemid 34761611)
13. Chlebowski R., Anderson G., Gass M. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA: 2010; 304 1684 1692
14. Prentice R., Manson J., Langer R. et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol: 2009; 170 12 23
15. LaCroix A. Z., Chlebowski R. T., Manson J. E. et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA: 2011; 305 1305 1314
16. Shah N. R., Borenstein J., Dubois R. W. Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. Menopause: 2005; 12 668 678 (Pubitemid 41669118)
17. Greiser C. M., Greiser E. M., Doren M. Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials. Hum Reprod Update: 2005; 11 561 573 (Pubitemid 41631307)
18. Lee S. A., Ross R. K., Pike M. C. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer: 2005; 92 2049 2058 (Pubitemid 40897429)
19. Collins J. A., Blake J. M., Crosignani P. G. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update: 2005; 11 545 560 (Pubitemid 41631306)
20. Col N. F., Hirota L. K., Orr R. K. et al. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol: 2001; 19 2357 2363 (Pubitemid 32372327)
21. Holmberg L., Anderson H. HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped. Lancet: 2004; 363 453 455 (Pubitemid 38210063)
22. von Schoultz E., Rutqvist L. E. Stockholm Breast Cancer Study Group Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst: 2005; 97 533 535 (Pubitemid 40590435)
23. Kenemans P., Bundred N. J., Foidart J. M. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol: 2009; 10 135 146
24. Cardozo L., Bachmann G., McClish D. et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol: 1998; 92 722 727 (Pubitemid 28440818)
25. Suckling J., Lethaby A., Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev: 2003; 4 CD001500
26. North American Menopause Society Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause: 2010; 17 242 255
27. Mettler L., Olsen P. G. Long-term treatment of atrophic vaginitis with low-dose oestradiol vaginal tablets. Maturitas: 1991; 14 23 31
28. Weisberg E., Ayton R., Darling G. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric: 2005; 8 83 92 (Pubitemid 40675125)
29. Gerbaldo D., Ferraiolo A., Croce S. et al. Endometrial morphology after 12Â months of vaginal oestriol therapy in postmenopausal women. Maturitas: 1991; 13 269 274
30. Luisi M., Franchi F., Kicovic P. M. A group-comparative study of effects of Ovestin® cream versus Premarin cream in postmenopausal women with vaginal atrophy. Maturitas: 1980; 2 311 319 (Pubitemid 11170808)
31. Buhling K. J., Eydeler U., Borregaard S. et al. Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries. Arzneimittelforschung: 2012; 62 378 383
32. Mazur D., Vens-Cappell B., Lohmann K. et al. Fractionated use of a 17β estradiol cream for the treatment of vaginal atrophy in postmenopausal women. Geburtsh Frauenheilk: 2005; 65 584 589 (Pubitemid 40917147)
33. Simon J. A., Komi J. Vulvovaginal atrophy negatively impacts sexual function, psychosocial wellbeing, and partner relationships. N Am Menopause Assoc: 2007; 10 3 6
34. Graziottin A. Sexuality in the Menopause. In: Studd J. ed. The Yearbook of Royal College of Obstetrics and Gynecologists. London RCOG Press: 1997; 201 209
35. Kendall A., Dowsett M., Folkerd E. et al. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol: 2006; 17 584 587
36. Wills S., Ravipati A., Venuturumilli P. et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract: 2012; 8 144 148
37. Dew J. E., Wren B. G., Eden J. A. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric: 2003; 6 45 52 (Pubitemid 36398872)
38. Trevoux R., van der Velden W. H., Popović D. Ovestin vaginal cream and suppositories for the treatment of menopausal vaginal atrophy. Reproduccion: 1982; 6 101 106 (Pubitemid 13241390)
39. Griesser H., Skonietzki S., Fischer T. et al. Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2 mg and 0.03 mg estriol. Maturitas: 2012; 71 360 368
40. Pfeiler G., Glatz C., Königsberg R. Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. Climacteric: 2011; 14 339 344
41. Biglia N., Peano E., Sgandurra P. et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol: 2010; 26 404 412
42. Mattsson L. A., Cullberg G. Vaginal absorption of two estriol preparations. A comparative study in postmenopausal women. Acta Obstet Gynecol Scand: 1983; 62 393 396 (Pubitemid 14213523)
43. Neven P., Donders G., Moegele M. et al. Ultra-low dose vaginal estriol and Lactobacillus acidophilus (Gynoflor®) in early breast cancer survivors on aromatase inhibitors: pharmacokinetic, efficacy and safety results from a phase I study. San Antonio Breast Cancer Symposium: 2012; Poster Presentation
44. Taylor A. H., Guzail M., Al-Azzawi F. Differential expression of oestrogen receptor isoforms and androgen receptor in the normal vulva and vagina compared with vulval lichen sclerosus and chronic vaginitis. Br J Dermatol: 2008; 158 319 328
45. Witherby S., Johnson J., Demers L. et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist: 2011; 16 424 431
46. Bygdeman M., Swahn M. L. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas: 1996; 23 259 263 (Pubitemid 26000605)
47. Sturdee D. W., Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric: 2010; 13 509 522